Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aspire Biopharma Holdings, Inc. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, JIANFENG SONG, within a single distinct art unit. JIANFENG SONG is the busiest examiner, overseeing the 1 pending office action. The company's current prosecution activity is concentrated on this single filing within the Biotechnology & Pharmaceuticals sector.
With only a single distinct examiner and a single distinct art unit involved, the company's prosecution strategy is entirely centralized. This allows for a direct and concentrated effort to address the 1 pending office action without the need to coordinate across multiple USPTO departments. The role of JIANFENG SONG is central to the company's current patent goals in Biotechnology & Pharmaceuticals, as there are no other pending matters or distinct examiners involved in the portfolio at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.3% | +33.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19348728 | ORAL MUCOSAL FORMULATIONS OF ASPIRIN | SONG, JIANFENG | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19348728 | ORAL MUCOSAL FORMULATIONS OF ASPIRIN | SONG, JIANFENG | 1613 | §103DP | Final Rejection | — | Pending | Oct 02, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial